fda cites risks of novartis drug a wsj news roundup washington the food and drug administration released a postmarketing safety review of exjade a novartis ag drug that removes excess iron in patients undergoing regular blood transfusions in may the fda warned the drug might be linked to kidney failure and eight deaths and novartis of switzerland sent out a letter to doctors warning them of the possibility exjade was associated with kidney failure and a blood disorder known as cytopenia now the agency in its first formal postmarketing safety review of a recently approved drug said it received reports of suspected adverse drug reactions linked to exjade including deaths in adults the agency said the cause of death in most cases was due to progression or complication of the underlying disease a spokeswoman for novartis wasnt available for comment 
